<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="847">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04694573</url>
  </required_header>
  <id_info>
    <org_study_id>CTS Covid-19 Serum Studies</org_study_id>
    <nct_id>NCT04694573</nct_id>
  </id_info>
  <brief_title>Multicenter CTS Pre-and Post-Transplantation Covid-19 Serum Studies</brief_title>
  <official_title>Collaborative Transplant Study (CTS) Pre- and Post-Transplantation Covid-19 Serum Studies: Antibody Development Following a SARS-CoV-2 Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Heidelberg University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Heidelberg University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Covid-19 Serum Study is a prospective case-control study in&#xD;
&#xD;
        1. kidney or liver transplanted patients being hospitalized due to an infection with Severe&#xD;
           Acute Respiratory Syndrome Coronavirus Type 2 (SARS-CoV-2) after transplantation (TX)&#xD;
           (POST-TX Covid-19 Serum Study)&#xD;
&#xD;
           or&#xD;
&#xD;
        2. patients receiving kidney or liver transplantation after having had a SARS-CoV-2&#xD;
           infection (PRE-TX Covid-19 Serum Study)&#xD;
&#xD;
      The aim of this study is to evaluate the development of de novo donor specific antibodies&#xD;
      (dnDSA) in transplanted patients being hospitalized due to an infection with SARS-CoV-2&#xD;
      (POST-TX Covid-19 Serum Study) as well as in patients receiving kidney or liver&#xD;
      transplantation after having had an infection with SARS-CoV-2 prior to transplantation&#xD;
      (PRE-TX Covid-19 Serum Study).&#xD;
&#xD;
      Further, the investigators will evaluate possible consequences of having had a SARS-CoV-2&#xD;
      infection prior or after liver or kidney transplantation with regard to graft survival and&#xD;
      incidence of graft rejection episodes as well as SARS-CoV-2 specific antibody development&#xD;
      after SARS-CoV-2 infection.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 28, 2020</start_date>
  <completion_date type="Anticipated">December 28, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 28, 2021</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>5 Years</target_duration>
  <primary_outcome>
    <measure>Change in dnDSA development (PRE-TX Covid-19 Serum Study)</measure>
    <time_frame>Year 1, 2, 3, 5 after day of transplantation</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in dnDSA development (POST-TX Covid-19 Serum Study)</measure>
    <time_frame>at day 60-90 after being hospitalized due to Covid-19; 1,2,3,5 years after day of hospitalization due to Covid-19</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Graft Survival (PRE-TX Covid-19 Serum-Study)</measure>
    <time_frame>Year 1, 2, 3, 5 after day of transplantation</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Graft Survival (Post-TX Covid-19 Serum-Study)</measure>
    <time_frame>at day 60-90 after being hospitalized due to Covid-19; 1,2,3,5 years after day of hospitalization due to Covid-19</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of graft rejection (PRE-TX Covid-19 Serum Study)</measure>
    <time_frame>Year 1, 2, 3, 5 after day of transplantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of graft rejection (POST-TX Covid-19 Serum Study)</measure>
    <time_frame>at day 60-90 after being hospitalized due to Covid-19; 1,2,3,5 years after day of hospitalization due to Covid-19</time_frame>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Covid19</condition>
  <condition>Kidney Transplant; Complications</condition>
  <condition>Kidney Transplant Failure and Rejection</condition>
  <condition>Liver Transplant; Complications</condition>
  <condition>Liver Transplant Failure and Rejection</condition>
  <arm_group>
    <arm_group_label>POST-TX Covid-19 Serum Study Case</arm_group_label>
    <description>Kidney or liver-transplanted patients being hospitalized due to an infection with SARS-CoV-2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>POST-TX Covid-19 Serum Study Control</arm_group_label>
    <description>2 matched controls without SARS-CoV-2 infection after TX; matching according to&#xD;
age (18-34, 35-59, 60-75 years)&#xD;
sex&#xD;
type of transplantation&#xD;
time after transplantation (0-180, 181-365, 366-1095, 1096-2555, &gt;2555 days after TX)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PRE-TX Covid-19 Serum Study Case</arm_group_label>
    <description>Patients being kidney or liver-transplanted after having had an infection with SARS-CoV-2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PRE-TX Covid-19 Serum Study Control</arm_group_label>
    <description>2 matched controls without SARS-CoV-2 infection prior to TX; matching according to&#xD;
age(18-34, 35-59, 60-75 years)&#xD;
sex&#xD;
type of transplantation</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Serum; EDTA&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Kidney- or liver transplant recipients with a SARS-CoV-2 infection prior to transplantation&#xD;
        (PRE-TX Covid-19 Serum Study) or a SARS-CoV-2 infection after transplantation (POST-TX&#xD;
        Covid-19 Serum Study), 2 matched controls&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Kidney-transplant recipients and full-size liver-recipients (de-novo or&#xD;
             re-transplanted)&#xD;
&#xD;
          -  Participant or legal guardian is willing and able to give informed consent for&#xD;
             participation in the trial&#xD;
&#xD;
          -  SARS-CoV-2 infection before transplantation (PRE-TX Covid-19 Serum Study) or after&#xD;
             transplantation (POST-TX Covid-19 Serum Study)&#xD;
&#xD;
        Specific Inclusion Criteria for PRE-TX Covid-19 Serum Study:&#xD;
&#xD;
          -  Kidney or liver transplantation between Dec 17,2020 - Dec 17, 2021&#xD;
&#xD;
        Specific Inclusion Criteria for POST-TX Covid-19 Serum Study:&#xD;
&#xD;
          -  Hospitalization due to SARS-CoV-2 infection in between Dec 17,2020 - Dec 17, 2021&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participants not meeting the inclusion criteria&#xD;
&#xD;
          -  multi-organ transplant recipients&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Caner Suesal, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institute of Immunology Heidelberg</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Christian Morath, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Nephrology, Heidelberg</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Caner Suesal, Professor</last_name>
    <phone>+49 (0) 6221 56-5545</phone>
    <email>caner.suesal@med.uni-heidelberg.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Christian Morath, Professor</last_name>
    <phone>+49 (0) 6221 91120</phone>
    <email>christian.morath@med.uni-heidelberg.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Nierenzentrum Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <state>DE</state>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christian Morath, Professor</last_name>
      <phone>+49 (0)6221-91120</phone>
      <email>christian.morath@med.uni-heidelberg.de</email>
    </contact>
    <contact_backup>
      <last_name>Louise Benning, Dr.med.</last_name>
      <email>louise.benning@med.uni-heidelberg.de</email>
    </contact_backup>
    <investigator>
      <last_name>Christian Morath, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Caner SÃ¼sal, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>December 28, 2020</study_first_submitted>
  <study_first_submitted_qc>January 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 5, 2021</study_first_posted>
  <last_update_submitted>January 15, 2021</last_update_submitted>
  <last_update_submitted_qc>January 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Heidelberg University</investigator_affiliation>
    <investigator_full_name>Caner Suesal</investigator_full_name>
    <investigator_title>Professor, Institute of Immunology</investigator_title>
  </responsible_party>
  <keyword>Covid-19</keyword>
  <keyword>SARS-CoV-2</keyword>
  <keyword>Kidney Transplantation</keyword>
  <keyword>Liver Transplantation</keyword>
  <keyword>donor-specific antibodies</keyword>
  <keyword>dnDSA</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

